OrthoPediatrics (NASDAQ:KIDS) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut shares of OrthoPediatrics (NASDAQ:KIDS - Free Report) from a hold rating to a sell rating in a report published on Friday morning.

A number of other research analysts have also weighed in on KIDS. Needham & Company LLC reissued a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. BTIG Research reissued a "buy" rating on shares of OrthoPediatrics in a report on Monday, July 14th. Piper Sandler decreased their target price on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Truist Financial decreased their target price on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.83.

OrthoPediatrics Stock Up 3.6%

Shares of KIDS traded up $0.79 during mid-day trading on Friday, hitting $22.67. 30,993 shares of the company's stock were exchanged, compared to its average volume of 196,470. The company has a market cap of $550.59 million, a PE ratio of -12.89 and a beta of 1.10. OrthoPediatrics has a 52 week low of $19.52 and a 52 week high of $34.77. The company has a 50-day simple moving average of $21.58 and a 200 day simple moving average of $23.02. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.19 and a quick ratio of 2.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The company had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. OrthoPediatrics had a negative return on equity of 7.03% and a negative net margin of 19.15%. On average, research analysts forecast that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Institutional Trading of OrthoPediatrics

A number of institutional investors have recently modified their holdings of KIDS. KLP Kapitalforvaltning AS bought a new stake in shares of OrthoPediatrics during the 4th quarter valued at $79,000. Wells Fargo & Company MN raised its holdings in shares of OrthoPediatrics by 31.1% during the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after buying an additional 2,338 shares in the last quarter. PDT Partners LLC acquired a new position in shares of OrthoPediatrics during the 1st quarter worth $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after buying an additional 645 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of OrthoPediatrics by 4,618.2% during the 1st quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock worth $261,000 after buying an additional 10,391 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.